{"schema_version":"secwatch.filing_event.v1","accession":"0001860742-26-000060","form_type":"8-K","ticker":"BLCO","cik":"0001860742","company_name":"Bausch & Lomb Corp","filed_at":"2026-04-29T23:59:59+00:00","discovered_at":"2026-05-14T18:02:33.167857+00:00","generated_at":"2026-05-15T02:24:01.879977+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Bausch + Lomb Q1 2026 revenue $1.244B (+9% YoY), raises full-year guidance","bullets":["Revenue $1.244B, up 9% reported and 6% constant currency YoY; GAAP net loss narrowed to $71M from $212M.","Adjusted EBITDA (non-GAAP) $189M vs $98M prior year; adjusted EPS $0.05 vs -$0.15.","Raising 2026 revenue guidance to $5.42B-$5.52B (was $5.375B-$5.475B) and Adj. EBITDA ex-IPR&D to $1.01B-$1.06B.","Pharmaceuticals segment grew 12% constant currency; MIEBO (+33%) and XIIDRA (+30%) led growth.","Vision Care +5% constant currency; Surgical +1% constant currency; double-digit growth in daily SiHy lenses."],"urls":{"canonical":"https://secwatch.observer/filing/0001860742-26-000060","json":"https://secwatch.observer/filing/0001860742-26-000060.json","markdown":"https://secwatch.observer/filing/0001860742-26-000060.md","text":"https://secwatch.observer/filing/0001860742-26-000060.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1860742/000186074226000060/0001860742-26-000060-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1860742/000186074226000060/blco-20260429.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T02:24:01.879977+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"13d08072072cb982c0054764c699ccdbfe7c72f5","claim":"Bausch & Lomb Corp reported the quarter ended March 31, 2026 results: revenue $1.244 billion, net income $71 million, EPS ($0.20). Guidance raised.","evidence_excerpt":"1933, as amended. --- EX-99.1 (EX-99.1) --- Bausch + Lomb Announces First-Quarter 2026 Results, Raises Guidance Based on Strong Performance and Positive Outlook • Revenue of $1.244 Billion • Revenue Grew 9% as Reported and 6% on a Constant Currency 1 Basis Compared to the First Quarter of 2025 • GAAP Net Loss Attributable to Bausch + Lomb Corporation of $71 Million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1860742/000186074226000060/0001860742-26-000060-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2026"},{"label":"Revenue","value":"$1.244 billion"},{"label":"Net income","value":"$71 million"},{"label":"EPS","value":"($0.20)"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}